Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer

Introduction Delayed onset of immune‐related adverse events following immune‐checkpoint inhibitor discontinuation is underrecognized because of little available evidence. Case presentation A 50‐year‐old man with metastatic renal cell carcinoma (Case 1) and 58‐year‐old woman with renal cell carcinoma...

Full description

Bibliographic Details
Main Authors:	Yasutomo Nakai, Tomoyuki Otsuka, Takako Inoue, Takatoshi Nawa, Koji Hatano, Yoshiyuki Yamamoto, Akira Nagahara, Masashi Nakayama, Ken‐ichi Kakimoto, Kazuo Nishimura
Format:	Article
Language:	English
Published:	Wiley 2021-09-01
Series:	IJU Case Reports
Subjects:	delayed onset immune‐checkpoint inhibitor immune‐related adverse events renal cell carcinoma
Online Access:	https://doi.org/10.1002/iju5.12338

Similar Items

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
by: Akinaru Yamamoto, et al.
Published: (2020-11-01)

Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study
by: Yukio Kadokawa, et al.
Published: (2023-02-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
by: Nobuyuki Nakajima, et al.
Published: (2020-09-01)

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report
by: Takaaki Arigami, et al.
Published: (2020-10-01)

Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer
by: Seiya Ichihara, et al.
Published: (2023-01-01)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
by: Takuya Segawa, et al.
Published: (2023-03-01)

Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
by: Yuki Nishimura, et al.
Published: (2023-03-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
by: Katsuhiro Yoshimura, MD, PhD, et al.
Published: (2021-11-01)

Regulation of CD8+ T Cells and Antitumor Immunity by Notch Signaling
by: Shin-ichi Tsukumo, et al.
Published: (2018-01-01)

Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia
by: Ingrid Aneman, et al.
Published: (2020-08-01)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
by: Hirofumi Watanabe, et al.
Published: (2020-10-01)

Molecular Farming of Pembrolizumab and Nivolumab
by: Michael C. Stark, et al.
Published: (2023-06-01)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
by: Yusuke Iikura, et al.
Published: (2022-07-01)

Pericardial effusion under nivolumab: case-reports and review of the literature
by: Saade Anastasia, et al.
Published: (2019-10-01)

Nivolumab associated vasculopathy: A novel mechanism
by: Adeeb Haroon, MS, et al.
Published: (2022-04-01)

Bilateral corneal perforation in Ipilimumab/Nivolumab - associated peripheral ulcerative keratitis
by: Julia Aschauer, et al.
Published: (2022-12-01)

Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
by: Kenji Takada, et al.
Published: (2021-06-01)

The burden of infant group B streptococcal infections in Ontario: Analysis of administrative data to estimate the potential benefits of new vaccines
by: James Hartley, et al.
Published: (2019-01-01)

Development of three endocrinopathies under nivolumab therapy
by: Anastasia A. Glibka, et al.
Published: (2023-02-01)

Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
by: L. Yu. Vladimirova, et al.
Published: (2021-08-01)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
by: Iñigo Les, et al.
Published: (2021-01-01)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
by: Bianca Gautron Moura, et al.
Published: (2022-12-01)

Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report
by: Kuniyasu Takagi, et al.
Published: (2021-10-01)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
by: Shinichiro Kanda, et al.
Published: (2023-10-01)

Clinical utility of nivolumab in the treatment of advanced melanoma
by: Asmar R, et al.
Published: (2016-02-01)

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma
by: Mathew R. Birnbaum, BS, et al.
Published: (2017-05-01)

Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer
by: Hui Yang, et al.
Published: (2021-10-01)

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
by: Shohei Watanabe, et al.
Published: (2021-12-01)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
by: Boudewijn Sweep, et al.
Published: (2021-11-01)

Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
by: Amruth R. Palla, et al.
Published: (2016-11-01)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
by: Koji Iinuma, et al.
Published: (2021-04-01)

Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid
by: Maria L. Mihailescu, et al.
Published: (2020-12-01)

Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report
by: Fumi Kikuchi, et al.
Published: (2021-04-01)

Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report
by: Reina Miyamoto, et al.
Published: (2020-06-01)

The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database
by: Tomoyuki Koguchi, et al.
Published: (2023-11-01)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
by: Morten Fink, et al.
Published: (2021-11-01)

Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab
by: Alexia Monastirioti, et al.
Published: (2022-09-01)